CMS to Lower Prices on 15 Major Medicare Part D Drugs by 2027
CMS announces reduced prices for 15 key Medicare Part D drugs starting in 2027, following the Inflation Reduction Act negotiations, targeting major cost savings in Medicare spending.
Pennsylvania's Act 77 Targets PBM Practices Amid Pharmacy Closures
Pennsylvania's Act 77 introduces new regulations on pharmacy benefit managers to address pharmacy closures and improve transparency in drug pricing and reimbursements, impacting 24% of the state's insurance market.
Mintz IRA Update Q3 2025 Analyzes Inflation Reduction Act Impact on Pharma
Stay informed on the latest Q3 2025 developments in the Inflation Reduction Act's impact on pharmaceutical supply chains, Medicare negotiation programs, and drug pricing reforms with the Mintz IRA Update.
North Carolina Employers Explore Transparent Pharmacy Benefit Managers Amid Cost and Compliance Concerns
North Carolina employers are shifting toward transparent pharmacy benefit managers to address rising drug costs and compliance risks. Learn how alternative PBMs impact insurance affordability and market dynamics.
Direct-to-Consumer Drug Sales: Implications for U.S. Pharma and Insurance Markets
Pharmaceutical companies are adopting direct-to-consumer drug sales, bypassing insurers and PBMs. This strategy impacts drug pricing, patient out-of-pocket costs, and insurance market dynamics in the U.S.
U.S. Health Policy and Insurance Trends: Veterans Access, Behavioral Health, Drug Pricing, and Public Health
Explore key U.S. health policy and insurance sector updates covering veterans' care access reforms, behavioral health workforce challenges, prescription drug pricing shifts, public health threats, and innovation in healthcare delivery.
AMA Report Highlights Market Concentration Among PBMs and Calls for Greater Transparency
The AMA report reveals high market concentration among pharmacy benefit managers (PBMs), vertical integration with insurers, and calls for increased transparency and regulatory reforms to control drug prices and enhance competition.
Trump Administration Advances Medicare Drug Price Negotiation Amid Industry Concerns
The Trump administration proceeds with the third cycle of Medicare drug price negotiations, addressing Part B drug inclusion and sparking pharmaceutical industry concerns about pricing and implementation.
North Carolina Legislature Advances Transparency and Regulation for Pharmacy Benefit Managers
North Carolina moves forward with legislative efforts to regulate pharmacy benefit managers, aiming to increase transparency and fair reimbursement for independent pharmacies amid rising drug prices.
Medicare Expansion for GLP-1 Agonists Balances Clinical Gains and Cost Risks
New analysis projects increased Medicare spending with expanded GLP-1 receptor agonist coverage for obesity, highlighting clinical benefits and financial challenges.